Company Overview of Histogenics Corporation
Histogenics Corporation, a biologics company, develops, markets, and commercializes regenerative medicine products for the musculoskeletal segment of the marketplace. The company focuses on regenerative medicine technologies, including cell-based therapies, tissue engineering, and biologics. It offers NeoCart, a cartilage-like tissue implant for treating damage to the articular cartilage of the knee using biological and cell-based therapy; and regenerative medicine platform that combines cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. The compan...
830 Winter Street
Waltham, MA 02451
Founded in 2000
Key Executives for Histogenics Corporation
Founder and Member of Scientific Advisory Board
Senior Vice President of Manufacturing
Compensation as of Fiscal Year 2014.
Histogenics Corporation Key Developments
Histogenics Appoints Kathleen Large, R.N., M.S., to Vice President of Clinical Operations
Jul 2 14
Histogenics Corporation announced the appointment of Kathleen Large, R.N., M.S., to Vice President of Clinical Operations. Ms. Large will be responsible for management of the company's clinical programs, including the ongoing Phase 3 trial of NeoCart(R), studying the treatment of certain knee cartilage injuries. Prior to joining Histogenics, Ms. Large most recently served as Director, Early Stage Development and Strategic Site Alliances at Millennium Pharmaceuticals.
Histogenics Corporation Appoints Adam Gridley as President and Chief Executive Officer and Member of Board of Director
May 12 14
Histogenics Corporation announced the appointment of Adam Gridley to President and Chief Executive Officer and as a member of the company's Board of Directors. Mr. Gridley brings over 20 years of proven results in the medical device and pharmaceutical industries, with a combination of transactional and public markets experience as well as strong operational leadership and product development expertise. Prior to joining Histogenics, Mr. Gridley most recently served as Senior Vice President, Technical Operations at Merz.
Histogenics Announces Appointment of John H. Johnson to its Board of Directors
Nov 14 13
Histogenics Corporation announced that John H. Johnson has been appointed to the company's board of directors. Mr. Johnson is currently the chairman, president and chief executive officer of Dendreon Corporation. Prior to joining Dendreon, Mr. Johnson was the chief executive officer and a member of the board of directors of Savient Pharmaceuticals Inc., from January 2011 through January 2012.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 18, 2013